ArticleAlzheimer's & dementia (New York, N. Y.)2015

A 24-week study to evaluate the effect of rilapladib on cognition and cerebrospinal fluid biomarkers of Alzheimer's disease.

Gareth Maher-Edwards et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.